NECTAR LIFESCIENCES LTD.
NECLIFE · General/Diversified · NSE
₹12
Current Market Price
Fair Value (DCF)
₹42
Margin of Safety
+253.3%
Updated just now
YieldIQ Score
37/100
Piotroski F-Score
5/9
Economic Moat
None
Confidence
60%
ROE
—
Debt/Equity
0.64
WACC
11.1%
Market Cap
₹229 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
—
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
—
Leverage vs earnings
Interest Coverage
-1.1×
EBIT covers interest
Current Ratio
1.21×
Short-term liquidity
Asset Turnover
0.82×
Revenue per ₹ of assets
Revenue CAGR (3Y)
0.0%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹11.79
Bear case
₹27.5
MoS +57.1%
Base case
₹41.66
MoS +71.7%
Bull case
₹93.99
MoS +87.5%
Ratio Trends
NECLIFE · last 4 annual periods
ROE
-11.9%
ROCE
-1.4%
Operating Margin
—
Debt / Equity
0.61×
PE
18.7×
EV / EBITDA
10.5×
Historical Financials
NECLIFE · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹1669 Cr | ₹1524 Cr | ₹1684 Cr | ₹1670 Cr | +0.0% |
| EBITDA | ₹161 Cr | ₹99.5 Cr | ₹169 Cr | ₹-22.1 Cr | — |
| EBIT | — | — | — | — | — |
| PAT | ₹25.0 Cr | ₹-24.2 Cr | ₹5.0 Cr | ₹-114 Cr | — |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹95.0 Cr | ₹134 Cr | ₹225 Cr | ₹169 Cr | +21.3% |
| CapEx | ₹-25.0 Cr | ₹-30.1 Cr | ₹-29.4 Cr | ₹-43.8 Cr | — |
| FCF | ₹70.0 Cr | ₹104 Cr | ₹195 Cr | ₹126 Cr | +21.5% |
| Total Assets | ₹2391 Cr | ₹2189 Cr | ₹2191 Cr | ₹2047 Cr | -5.0% |
| Total Debt | ₹860 Cr | ₹754 Cr | ₹636 Cr | ₹582 Cr | -12.2% |
| Shareholders' Equity | ₹1088 Cr | ₹1065 Cr | ₹1069 Cr | ₹956 Cr | -4.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
NECLIFE vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| AAREYDRUGS AAREYDRUGS | — | — | Pending | 2.9% | — |
| BROOKS BROOKS | — | — | Pending | -10.2% | — |
| BAFNAPH BAFNAPH | — | — | Pending | 4.9% | — |
| MEDICO MEDICO | — | — | Pending | 16.2% | — |
| NATCAPSUQ NATCAPSUQ | — | — | Pending | 0.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for NECLIFE in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. NECTAR LIFESCIENCES LTD. (NECLIFE.NS) trades at 11.79 vs a model fair value of 41.66, a gap of 253.3%. Piotroski F-score: 5/9. Moat label...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of NECLIFE →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for NECLIFE →
Compare
Head-to-head with peers
Compare NECLIFE side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse NECLIFENow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.